Studies of relationships between the GLUT10 Ala206Thr polymorphism and impaired insulin secretion.
OBJECTIVE
This study aimed to investigate if the previously observed association between the GLUT10 Ala206Thr polymorphism and variation in fasting and oral glucose-induced serum insulin concentrations could be replicated in a large-scale population-based cohort of Danish whites.


METHODS
The GLUT10 Ala206Thr polymorphism was genotyped in a case-control study of 880 Type 2 diabetic patients and 4372 glucose-tolerant control subjects. The latter group was also enrolled in an assessment of fasting and post-OGTT circulating levels of plasma glucose and serum insulin in relation to genotype. The variant was genotyped by analysis of PCR-generated primer extension by matrix-assisted laser desorption/ionization time-of-flight analysis.


RESULTS
The Ala206Thr variant was equally frequent among Type 2 diabetic patients and glucose-tolerant subjects (P = 0.9) and there was no difference in the distribution of genotype groups (P = 1.0). In the 4372 glucose-tolerant subjects there was no statistically significant association between the polymorphism and levels of fasting and post-oral glucose tolerance test plasma glucose and serum insulin along with the insulinogenic index and the homeostasis model of assessment for insulin resistance and insulin secretion. Likewise, in an age-stratified subgroup comprising 1264 subjects, we observed no relationships between the GLUT10 polymorphism and the selected metabolic features.


CONCLUSIONS
The GLUT10 Ala206Thr polymorphism is not associated with Type 2 diabetes in the Danish population. Furthermore, in the present large-scale cohort, the polymorphism does not associate with phenotypes such as fasting and oral glucose-induced levels of plasma glucose and serum insulin.
Steno Diabetes Center, Gentofte, Denmark. csro@steno.dk
C S
CS
Rose
G
G
Andersen
Y H
YH
Hamid
C
C
Glümer
T
T
Drivsholm
K
K
Borch-Johnsen
T
T
Jørgensen
O
O
Pedersen
T
T
Hansen
D000328:Adult; D000409:Alanine / Q000235:genetics; D001786:Blood Glucose / Q000032:analysis; D016022:Case-Control Studies; D003062:Codon / Q000235:genetics; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000235:genetics*; D005260:Female; D005787:Gene Frequency / Q000235:genetics; D005838:Genotype; D005951:Glucose Tolerance Test / Q000379:methods; D051246:Glucose Transport Proteins, Facilitative; D006801:Humans; D007328:Insulin / Q000097:blood* / Q000235:genetics; D007333:Insulin Resistance / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009004:Monosaccharide Transport Proteins / Q000235:genetics*; D010641:Phenotype; D011110:Polymorphism, Genetic / Q000235:genetics*; D013912:Threonine / Q000235:genetics
D001786:Blood Glucose; D003062:Codon; D051246:Glucose Transport Proteins, Facilitative; D007328:Insulin; D009004:Monosaccharide Transport Proteins; C430746:SLC2A10 protein, human; D013912:Threonine; D000409:Alanine